Page 136 - Haematologica3

M.L. Nijland et al. 2011;9(1):36-41 e1.
23. Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues (4th ed). Lyon, France: International Agency for Research on Cancer. 2008.
24. Olsen E, Vonderheid E, Pimpinelli N, et al. Revisions to the staging and classification of mycosis fungoides and Sezary syn- drome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007;110(6):1713-1722.
25. Lopez-Guillermo A, Cid J, Salar A, et al. Peripheral T-cell lymphomas: initial fea- tures, natural history, and prognostic fac- tors in a series of 174 patients diagnosed according to the R.E.A.L. Classification. Ann Oncol. 1998;9(8):849-855.
26. Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26(25):4124-4130.
27. Jaffe ES, Harris NL, Stein H, Isaacson PG. Classification of lymphoid neoplasms: the microscope as a tool for disease discovery. Blood. 2008;112(12):4384-4399.
28. Arrowsmith ER, Macon WR, Kinney MC, et al. Peripheral T-cell lymphomas: clinical features and prognostic factors of 92 cases defined by the revised European American lymphoma classification. Leuk Lymphoma. 2003;44(2):241-249.
29. Ferreri AJ. Risk of CNS dissemination in extranodal lymphomas. Lancet Oncol. 2014;15(4):e159-169.
30. Zucca E, Roggero E, Bertoni F, Cavalli F.
Primary extranodal non-Hodgkin's lym- phomas. Part 1: Gastrointestinal, cutaneous and genitourinary lymphomas. Ann Oncol. 1997;8(8):727-737.
31. Tran H, Nourse J, Hall S, Green M, Griffiths L, Gandhi MK. Immunodeficiency-associ- ated lymphomas. Blood Rev. 2008;22(5):261-281.
32. Gisselbrecht C, Gaulard P, Lepage E, et al. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA). Blood. 1998;92(1):76-82.
33. Ekstrom Smedby K, Vajdic CM, Falster M, et al. Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. Blood. 2008;111(8):4029- 4038.
34. Wang SS, Flowers CR, Kadin ME, et al. Medical history, lifestyle, family history, and occupational risk factors for peripheral T-cell lymphomas: the InterLymph Non- Hodgkin Lymphoma Subtypes Project. J Natl Cancer Inst Monogr. 2014;2014(48):66-75.
35. Tsochatzis E, Vassilopoulos D, Deutsch M, Filiotou A, Tasidou A, Archimandritis AJ. Angioimmunoblastic T-cell lymphoma- associated arthritis: case report and litera- ture review. J Clin Rheumatol. 2005;11(6):326-328.
36. De Groof J, Rossen N, van Rhijn B, et al. P644 Epidemiology and characteristics of inflammatory bowel disease in a large pop- ulation-based cohort in the Netherlands. Poster presentations European Crohn's and Colitis Organisation, 2015.
37. The Netherlands Cancer Registry. 38. Statistics Netherlands (CBS).
39. National Institute of Public Health and the Environment (RIVM).
40. Hoshida Y, Li T, Dong Z, et al. Lymphoproliferative disorders in renal transplant patients in Japan. Int J Cancer. 2001;91(6):869-875.
41. Lin WC, Moore JO, Mann KP, Traweek ST, Smith C. Post transplant CD8+ gam- madelta T-cell lymphoma associated with human herpes virus-6 infection. Leuk Lymphoma. 1999;33(3-4):377-384.
42. Fisher SG, Fisher RI. The epidemiology of non-Hodgkin's lymphoma. Oncogene. 2004;23(38):6524-6534.
43. Barzilai A, Trau H, David M, et al. Mycosis fungoides associated with B-cell malignan- cies. Br J Dermatol. 2006;155(2):379-386.
44. Campidelli C, Sabattini E, Piccioli M, et al. Simultaneous occurrence of peripheral T- cell lymphoma unspecified and B-cell small lymphocytic lymphoma. Report of 2 cases. Hum Pathol. 2007;38(5):787-792.
45. Herro E, Dicaudo DJ, Davis MD, Weaver AL, Swanson DL. Review of contempora- neous mycosis fungoides and B-cell malig- nancy at Mayo Clinic. J Am Acad Dermatol. 2009;61(2):271-275.
46. Ko M, An J, Pastor WA, Koralov SB, Rajewsky K, Rao A. TET proteins and 5- methylcytosine oxidation in hematological cancers. Immunol Rev. 2015;263(1):6-21.
47. Solary E, Bernard OA, Tefferi A, Fuks F, Vainchenker W. The Ten-Eleven Translocation-2 (TET2) gene in hematopoiesis and hematopoietic diseases. Leukemia. 2014;28(3):485-496.
48. Pan F, Wingo TS, Zhao Z, et al. Tet2 loss leads to hypermutagenicity in haematopoi- etic stem/progenitor cells. Nat Commun. 2017;8:15102.
496
haematologica | 2018; 103(3)